

IASLC




IASLC 2022
Asia Conference
on Lung Cancer

OCTOBER 27-29, 2022 | NARA, JAPAN

PROGRAM BOOK

OCTOBER 27-29, 2022
NARA, JAPAN



#ACLC22

IASLC



2023 Latin America Conference on Lung Cancer

JANUARY 25-27, 2023 | MONTEVIDEO, URUGUAY

Register Now

Benefit from wide-ranging and multi-disciplinary content including keynote lectures, roundtable discussions, cancer control program and tobacco forum, oral abstracts, and poster presentations.

Early Registration ends November 18, 2022.

#LALCA23

lalca2023.iaslc.org



TABLE OF CONTENTS

WELCOME MESSAGE	5
IASLC & PROGRAM COMMITTEE	7
VENUE FLOORPLAN	9
PROGRAM	11
POSTER SESSIONS	21
EDUCATION AWARDS	29
ABSTRACT AUTHOR INDEX	31
INDUSTRY SUPPORTERS & EXHIBITORS	37
GENERAL INFORMATION	39



CONFERENCE SECRETARIAT

International Conference Services Ltd. (ICS)

Suite 710, 1201 West Pender Street, Vancouver, BC, Canada, V6E 2V2

Phone: +1 604 681 2153

www.icsevents.com

GLOBAL OFFICES

Vancouver, Toronto, Texas, London, Barcelona, Vienna,
Tokyo, Singapore

01

Welcome Message



#ACLC22



Welcome Message

On behalf of the International Association for the Study of Lung Cancer (IASLC), we are pleased to welcome you to the IASLC 2022 Asia Conference on Lung Cancer (ACLC2022) at Nara Prefectural Convention Center. We are thrilled that you join us again in a face-to-face meeting with virtual elements that will enhance participant's experience and allow anyone from anywhere to join this unique meeting. Over 400 participants are joining us in beautiful Nara to share information about the frontiers of clinical and basic research, clinical management, and multidisciplinary care.

We would like to extend our gratitude and thanks to all industry supporters and exhibitors for their support of the Asia Conference on Lung Cancer and the IASLC. Without them this Conference would not be possible.

Thank you for joining us in Nara.

We look forward to hosting all of you over the next couple of days.

Best Regards,



Tetsuya Mitsudomi

MD, PhD

*Department of Surgery,
Division of Thoracic Surgery
Kindai University
Faculty of Medicine*



Myung-Ju Ahn

MD, PhD

*Professor of Hematology
Samsung Medical Center*



James CH Yang

MD, PhD

*Superintendent, National Taiwan
University Cancer Center*

*Professor, Graduate Institute of
Oncology, National Taiwan University*

02

IASLC & Program Committee



#ACLC22



IASLC & Program Committee


International Association for the Study of Lung Cancer

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes nearly 6,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

- To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies.
- To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public
- To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.



IASLC INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Conquering Thoracic Cancers Worldwide

999 17th Street, Suite 200 - Denver, Colorado, 80202-2725

info@iaslc.org

1-855-464-2752

Program Committee

Advanced / Metastatic NSCLC

Caicun Zhou, Chair, China
 Dong Wan Kim, Republic of Korea
 Kazuhiko Nakagawa, Japan
 Daniel Tan, Singapore
 Solange Peters, Switzerland
 Misako Nagasaka, USA
 Jin-Yuan Shih, Taiwan
 Thanyanan Reungwetwattana, Thailand
 Chia-Chi Lin, Taiwan

Diagnosis, Imaging, and Bronchoscopy

Chao-Chi Ho, Chair, Taiwan
 Ho Yun Lee, Republic of Korea
 Shuji Sakai, Japan

Early Stage NSCLC

Young Tae Kim, Chair, Republic of Korea
 Yi-Long Wu, China
 Roy Herbst, USA
 Stephen Liu, USA
 Ichiro Yoshino, Japan
 Hidehito Horinouchi, Japan
 Jing-Shin Chen, Taiwan

Locally Advanced NSCLC

Ross Soo, Chair, Singapore
 Hong-Gyun Wu, Republic of Korea
 Luis Paz-Ares, Spain
 Terufumi Kato, Japan
 Isamu Okamoto, Japan
 Kayoko Ohnishi, Japan
 Sita Laksmi Andarini, Indonesia

Palliative and Supportive Care

Akira Inoue, Chair, Japan
 David Currow, Australia
 David Hui, USA

Risk Reduction, Early Detection, Epidemiology and Tobacco Control

Pan-Chyr Yang, Chair, Taiwan
 Abhishek Shankar, India

SCLC, Mesothelioma and Thymoma

Jie Wan, Chair, China
 Se Hoon Lee, Republic of Korea
 Yasushi Goto, Japan

Translational Science, Basic Science, and Pathology

Yasushi Yatabe, Chair, Japan
 Teh-Ying Chou, Taiwan
 Chong-Jen Yu, Taiwan

03

Venue Floorplan




#ACLC22




Venue Floorplan

Nara Prefectural Convention Center - 1F



Nara Prefectural Convention Center - 2F



04

Program



#ACLC22



Program

THURSDAY | OCTOBER 27, 2022



Registration Desk Opening Hours: 09:30 – 18:00

Speaker Preview Center Opening Hours: 09:30 – 17:00

EC01 - Early Career Workshop

Plenary Hall | Room 203 | 2F

- 10:00 – 12:00** Chairs: James Chin-Hsin Yang, Taiwan & Karen Kelly, USA
- 10:00 – 10:02** Welcome and Introduction
- 10:02 – 10:17** EC01.01: Challenges and/or Opportunities for Early Career Researchers
Derek De-Rui Huang, Taiwan
- 10:17 – 10:32** EC01.02: How to Improve Acceptance Rate of Manuscript into JTO
Ross Soo, Singapore
- 10:32 – 10:47** EC01.03: How to Set Up an Investigator Initiated Trial
Keunchil Park, Republic of Korea
- 10:47 – 11:02** EC01.04: How to Build an Engaging Presentation
Tony Mok, Hong Kong
- 11:02 – 11:17** EC01.05: How to Build Up Physician Scientists
Hiroyuki Yasuda, Japan
- 11:17 – 11:32** EC01.06: Benefits of Joining IASLC as a Young Doctor
Karen Kelly, USA
- 11:32 – 12:00** Q&A Discussion

WTO01 - Women in Thoracic Oncology

Breakout Room | Room 204 | 2F

- 10:30 – 12:00** Chairs: Myung-Ju Ahn, Republic of Korea & Tetsuya Mitsudomi, Japan
- 10:30 – 10:32** Welcome and Introduction
- 10:32 – 10:47** WTO01.01: How to Support Other Women's Voices in Meetings
Jie Wang, China
- 10:47 – 11:02** WTO01.02: How to Balance Family Life and Work as Women Doctor
Miyako Satouchi, Japan
- 11:02 – 11:17** WTO01.03: Experience of Thoracic Surgeon as Women Doctor
Hyo-Yeong Ahn, Republic of Korea
- 11:17 – 11:32** WTO01.04: How to Be a Good Mentor
Heather Wakelee, USA
- 11:32-11:47** WTO01.05: Hints for a Better Work Environment
Misako Nagasaka, USA
- 11:47-12:00** Q&A Discussion

12:00 - 12:30 Networking Lunch

Plenary Hall | Room 203 | 2F

Lunch will be provided

PL01 - Lung Cancer in Asia: Opportunities & Challenges

Plenary Hall | Room 203 | 2F

- 12:30 – 14:00** Chairs: Myung-Ju Ahn, Republic of Korea & Pan-Chyr Yang, Taiwan
- 12:30 – 12:32** Welcome and Introduction
- 12:32 - 12:52** PL01.01: Molecular Epidemiology of Lung Cancer in Asia
Yu-Ju Chen, Taiwan
- 12:52 - 13:12** PL01.02: Current Status of Clinical Trials of Lung Cancer and How to Improve Drug Accessibility in Asia
Ross Soo, Singapore
- 13:12 - 13:32** PL01.03: Medical Big Data of NSCLC Based on CDM (Common Data Model)
Akihiko Genma, Japan
- 13:32 - 13:52** PL01.04: Current CTONG Studies, Current Studies in Asia, Drug Accessibility
Yi-Long Wu, China
- 13:52 - 14:00** Q&A Discussion

ES01 - The Epidemiology and Lung Cancer Screening Programs in Asia

Plenary Hall | Room 203 | 2F

- 14:00 – 15:00** Chairs: Sita Andarini, Indonesia & Pan-Chyr Yang, Taiwan
- Track: Risk Reduction, Early Detection, Epidemiology and Tobacco Control**
- 14:00 – 14:02** Welcome and Introduction
- 14:02 - 14:14** ES01.01: Challenges of Lung Cancer Screening in Developing Countries in Asia
Abhishek Shankar, India
- 14:14 – 14:26** ES01.02: Current Status of Lung Cancer Screening in Japan
Kazuto Ashizawa, Japan
- 14:26 – 14:38** ES01.03: Lung Cancer Screening Program in Korea
Yeol Kim, Republic of Korea
- 14:38 – 14:50** ES01.04: Lung Cancer Screening for Non Smokers
Gee-Chen Chang, Taiwan
- 14:50 – 15:00** Q&A Discussion

ES02 - Perioperative Therapy Reloaded: Immunotherapy and Targeted Therapy for Early Stage NSCLC

Breakout Room | Room 204 | 2F

14:00 - 15:00 Chairs: Hidehito Horinouchi, Japan & Pham Cam Phuong, Vietnam

Track: Early Stage NSCLC

14:00 - 14:02 Welcome and Introduction

14:02 - 14:14 ES02.01: Practical Challenges Perioperative Systemic Therapy in Early Stage Lung Cancer (Endocrine, Hypothyroidism, Autoimmune, etc)

Sun Min Lim, Republic of Korea

14:14 - 14:26 ES02.02: How to Decide Neoadjuvant vs. Adjuvant Treatment

Junichi Soh, Japan

14:26 - 14:38 ES02.03: How We Select Patients for Chemo-Immuno Surgery vs. Chemo-Immuno-Radiation

Junko Tanizaki, Japan

14:38 - 14:50 ES02.04: Precision Selection of Patients Using Novel Biomarkers for Perioperative Treatment

Si-Yang Liu, China

14:50 - 15:00 Q&A Discussion

15:00 - 15:45 Networking Break Exhibit Hall | Room 201+202 | 2F

Refreshments will be provided

ES03 - New Horizons in Lung Cancer Diagnosis from Imaging

Plenary Hall | Room 203 | 2F

15:45 - 16:45 Chairs: Ho Yun Lee, Republic of Korea, Shuji Sakai, Japan

Track: Diagnosis, Imaging, and Bronchoscopy

15:45 - 15:47 Welcome and Introduction

15:47 - 15:59 ES03.01: Response Evaluation or Complications Related to Immunotherapy

Shuji Sakai, Japan

15:59 - 16:11 ES03.02: Lung MRI for Lung Cancer

Yoshiharu Ohno, Japan

16:11 - 16:23 ES03.03: AI in Lung Cancer

Joon Beom Seo, Republic of Korea

16:23 - 16:35 ES03.04: Imaging Findings for Precision Medicine

Geewon Lee, Republic of Korea

16:35 - 16:45 Q&A Discussion

ES04 - Advances in Multi-Modality Treatment of Locally Advanced NSCLC

Breakout Room | Room 204 | 2F

15:45 - 16:45 Chairs: Haruko Daga, Japan & Chee Lee, Australia

Track: Locally Advanced NSCLC

15:45 - 15:47 Welcome and Introduction

15:47 - 15:59 ES04.01: Advances in Radiation Therapy in the Era of Immunotherapy

Changhoon Song, Republic of Korea

15:59 - 16:11 ES04.02: Novel Immunotherapy Approaches Beyond Consolidation Durvalumab

Chee Lee, Australia

16:11 - 16:23 ES04.03: Molecular Targeted Therapy - Is There a Role?

Terufumi Kato, Japan

16:23 - 16:35 ES04.04: Survivorship Issues: Closing the Care Gap

Sita Andarini, Indonesia

16:35 - 16:45 Q&A Discussion

OA01 - Oral Abstract Session 1

Plenary Hall | Room 203 | 2F

17:00 - 18:00 Chairs: Karen Kelly, USA & Pan-Chyr Yang, Taiwan

17:00 - 17:12 OA01.01: Is Computed Tomographic Screening for Lung Cancer Associated with Lung Cancer Overdiagnosis Among Asian Women?

Hsiu-Hsi Chen, Taiwan

17:12 - 17:24 OA01.02: Operational Management Challenges in Continuing Lung Cancer Screening during COVID-19 Pandemic

Prerna Gautam, India

17:24 - 17:36 OA01.03: Safety of Lung Cancer Surgery in Patients with History of SARS-CoV-2 Infection In the Post-vaccination Era: A Single Center Experience

Somin Im, Republic of Korea

17:36 - 17:48 OA01.04: Biomarker Analysis from a Phase II Alternating Therapy with Osimertinib and Afatinib for EGFR-Mutated NSCLC (WJOG10818L)

Kimio Yonesaka, Japan

17:48 - 18:00 Q&A Discussion

Poster Viewing

Exhibit Hall | Room 201+202 | 2F

Refreshments will be provided

18:00 - 19:00 Poster Tour 1 & 2

18:00 - 19:00 Poster Viewing Reception A

For further details, please refer to the Poster Section, pages 24 - 26.

IS01 – Industry Symposium Sponsored by MSD K.K.: Advances in Treatment with Immune Checkpoint Inhibitors for NSCLC

Breakout Room | Room 204 | 2F

Refreshments will be provided

19:00 – 20:00 Chair: Makoto Maemondo, Japan

19:00 – 20:00 Advances in Treatment with Immune
Checkpoint Inhibitors for NSCLC

Masahiro Tsuboi, Japan

Program

FRIDAY | OCTOBER 28, 2022



Registration Desk Opening Hours: 08:00 – 16:00

Speaker Preview Center Opening Hours: 08:00 – 16:00

PL02 – New Horizons of Immunotherapy in Lung Cancer

Plenary Hall | Room 203 | 2F

- 08:45 – 10:15** Chairs: Karen Kelly, USA & Tetsuya Mitsudomi, Japan
- 08:45 – 08:47** Welcome and Introduction
- 08:47 – 08:57** Education Award Presentations
Tetsuya Mitsudomi, Japan
- 08:57 – 09:12** PL02.01: Revisiting Cancer Vaccine Using Neoantigen
Hirokazu Matsushita, Japan
- 09:12 – 09:27** PL02.02: CAR T Cell Therapy in Solid Tumors
Koji Tamada, Japan
- 09:27 – 09:42** PL02.03: Novel Antibodies Including BiTEs
Solange Peters, Switzerland
- 09:42 – 09:57** PL02.04: New Checkpoints
Chia-Chi (Josh) Lin, Taiwan
- 09:57 – 10:15** Q&A Discussion

10:15 – 10:45 Networking Break

Exhibit Hall | Room 201+202 | 2F

Refreshments will be provided

ES05 - Immunotherapy

Plenary Hall | Room 203 | 2F

- 10:45 – 11:45** Chairs: Solange Peters, Switzerland & Nobuyuki Yamamoto, Japan
- Track: Advanced/Metastatic NSCLC - Immunotherapy**
- 10:45 – 10:47** Welcome and Introduction
- 10:47 – 11:00** ES05.01: Personalized Immunotherapy
Myung-Ju Ahn, Republic of Korea
- 11:00 – 11:13** ES05.02: Immunotherapy in Special Population
Motoko Tachihara, Japan
- 11:13 – 11:26** ES05.03: Emerging Immunotherapy Combination
Solange Peters, Switzerland

- 11:26 – 11:39** ES05.04: IPRACTIC - A Proposed Statistical Analysis Pipeline For Blood Based Longitudinal Immunomonitoring For Immunotherapy Clinical Trial
Joe Yeong, Singapore
- 11:39 – 11:45** Q&A Discussion

ES06 - New Horizons in Lung Cancer Diagnosis: Bronchoscopy for Biopsy and Staging

Breakout Room | Room 204 | 2F

- 10:45 – 11:45** Chairs: Noriaki Kurimoto, Japan & Chong-Jen Yu, Taiwan
- Track: Diagnosis, Imaging, and Bronchoscopy**
- 10:45 – 10:47** Welcome and Introduction
- 10:47 – 10:59** ES06.01: Transbronchial Cryobiopsy for Peripheral Pulmonary Lesions
Yuji Matsumoto, Japan
- 10:59 – 11:11** ES06.02: Bronchoscopic Transparenchymal Nodule Access (BTPNA)
Jiayuan Sun, China
- 11:11 – 11:23** ES06.03: Robotic Bronchoscopy
David I K Fielding, Australia
- 11:23 – 11:35** ES06.04: Transesophageal Bronchoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-B-FNA)
Hwangbo Bin, Republic of Korea
- 11:35 – 11:45** Q&A Discussion

IS02 – Industry Symposium Sponsored by MERCK Healthcare KGaA: Decisive Moments in the Treatment of MET exon 14 Skipping NSCLC

Plenary Hall | Room 203 | 2F

Lunch will be provided

- 12:00 – 13:00** Chair: Terufumi Kato, Japan
- 12:00 – 12:05** A Moment to Welcome You
Terufumi Kato, Japan
- 12:05 – 12:15** Take a Moment to Consider Identification and Treatment
Yasushi Goto, Japan
- 12:15 – 12:25** A Moment of Clarity: Has our VISION for MET exon 14 Skipping Become a Reality?
Nir Peled, Israel

- 12:25 - 12:40** A Moment to Examine Treatment Outcomes and the VISION Study in Asian Patients
James Yang, Taiwan
- 12:40 - 12:50** Make Every Moment Matter: Optimising Treatment
Led by Terufumi Kato, Japan
- 12:50 - 13:00** A Moment to Reflect on *MET* exon 14 Skipping
Terufumi Kato, Japan

IS03 – Industry Symposium Sponsored by Physicians’ Education Resource®, LLC: Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

Breakout Room | Room 204 | 2F
Lunch will be provided

- 12:00 – 13:00** Chair: Solange Peters, Switzerland
- 12:00 - 12:05** Welcome, Introductions, Pre-Session Survey
Solange Peters, Switzerland
- 12:05 - 12:20** CEACAM5: What Is It, and How and Where Is It Expressed
Ross Soo, Singapore
- 12:20 - 12:30** Testing for CEACAM5: Does Tissue Play A Central Role?
Ming Tsao, Canada
- 12:30 - 12:45** Clinical Validation of CEACAM5 as a Therapeutic Target
Solange Peters, Switzerland
- 12:45 - 12:50** Post Session Survey
- 12:50 - 12:55** Panel Discussion
- 12:55 - 13:00** Question & Answer Session

OA02 – Oral Abstract Session 2

Plenary Hall | Room 203 | 2F

- 13:15 – 14:30** Chairs: Yasushi Goto, Japan & Keunchil Park, Republic of Korea
- 13:15 - 13:27** OA02.01: Differential Diagnosis of Rare Thoracic Tumors Characterized by Gene Rearrangement Using RNA Pan-Cancer Panel
Harumi Nakamura, Japan
- 13:27 - 13:39** OA02.02: The Association of Tumor Metastatic Score and Overall Survival in Patients with Stage IV Non-small Cell Lung Cancer Bearing Extra-thoracic Metastases
Yen-lin Chen, Taiwan
- 13:39 - 13:51** OA02.03: AKT Pathway as a Therapeutic Target to Constrain Lineage Plasticity Leading to Histological Transdifferentiation
Alvaro Quintanal-Villalonga, USA
- 13:51 - 14:03** OA02.04: A Phase Ib Study of AK112, a PD-1/VEGF Bispecific Antibody, in Combination with Etoposide and Carboplatin in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Shun Lu, China

- 14:03 - 14:15** OA02.05: Fear of Cancer Recurrence and its Predictors among Patients with Non-Small Cell Lung Cancer (NSCLC)
Wonyoung Jung, Republic of Korea
- 14:15 - 14:27** OA02.06: CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions
Misako Nagasaka, USA
- 14:27 - 14:30** Q&A Discussion

ES07 - Surgery for Early Stage NSCLC: Beyond Lobectomy

Plenary Hall | Room 203 | 2F

- 14:30 – 15:30** Chairs: Young Tae Kim, Republic of Korea & Ichiro Yoshino, Japan

Track: Early Stage NSCLC

- 14:30 -14:32** Welcome and Introduction
- 14:32 - 14:44** ES07.01: Current Evidence of Sublobar Resection for Lung Cancer
Hisashi Saji, Japan
- 14:44 - 14:56** ES07.02: Sublobar Resections for Early NSCLC - Pulmonary Function Preservation?
Wentao Fang, China
- 14:56 - 15:08** ES07.03: Oncologic Unmet Needs of Sublobar Resection
Samina Park, Switzerland
- 15:08 - 15:20** ES07.04: Robotic Surgery for Sublobar Resection
Seong Yong Park, Republic of Korea
- 15:20 - 15:30** Q&A Discussion

ES08 - SCLC

Breakout Room | Room 204 | 2F

- 14:30 – 15:30** Chairs: Miyako Satouchi, Japan & Chao-Chi Ho, Taiwan

Track: SCLC, Mesothelioma and Thymoma

- 14:30 -14:32** Welcome and Introduction
- 14:32 - 14:44** ES08.01: Chemotherapy for SCLC
Miyako Satouchi, Japan
- 14:44 - 14:56** ES08.02: Advances in immunotherapy in SCLC
Jie Wang, China
- 14:56 - 15:08** ES08.03: Carcinoid Tumor
Se-Hoon Lee, Republic of Korea
- 15:08 - 15:20** ES08.04: Radiation Therapy of Small Cell Lung Cancer
Yu Yang Soon, Singapore
- 15:20 - 15:30** Q&A Discussion

15:30 – 16:00 Networking Break

Exhibit Hall | Room 201+202 | 2F

Refreshments will be provided

ES09 - Therapeutic Challenges in Locally Advanced NSCLC

Plenary Hall | Room 203 | 2F

16:00 – 17:00 Chairs: Ross Soo, Singapore & Yuko Oya, Japan

Track: Locally Advanced NSCLC

- 16:00 – 16:02** Welcome and Introduction
- 16:02 – 16:15** ES09.01: Treatment Options After Progression on Consolidation Immune Checkpoint Inhibition
Qing Zhou, China
- 16:15 – 16:28** ES09.02: Consolidation Immunotherapy for Driver Oncogene Positive Unresectable NSCLC
Jii Bum Lee, Republic of Korea
- 16:28 – 16:41** ES09.03: Respiratory Emergencies in Unresectable NSCLC
Emily Stone, Australia
- 16:41 – 16:54** ES09.04: Approach to Immune-Related Pneumonitis: Detection, Management and Re-Challenge
Daichi Fujimoto, Japan
- 16:54 – 17:00** Q&A Discussion

ES10 - Palliative Care for Lung Cancer Patients

Breakout Room | Room 204 | 2F

16:00 – 17:00 Chairs: Shao-Yi Cheng, Taiwan & Akira Inoue, Japan

Track: Palliative and Supportive Care

- 16:00 – 16:02** Welcome and Introduction
- 16:02 – 16:14** ES10.01: Integration of Oncology Care and Palliative Care
David Hui, USA
- 16:14 – 16:26** ES10.02: Latest Pain Management
Yoshihisa Matsumoto, Japan
- 16:26 – 16:38** ES10.03: Home-Based Palliative Care
Chin-Yuan Shih, Taiwan
- 16:38 - 16:50** ES10.04: Advance Care Planning
Sun-Hyun Kim, Republic of Korea
- 16:50 - 17:00** Q&A Discussion

Poster Viewing

Exhibit Hall | Room 201+202 | 2F

Refreshments will be provided

- 17:00 - 18:30** Poster Tour 3
17:00 - 18:30 Poster Viewing Reception B

For further details, please refer to the Poster Section, pages 24 - 26.

IS04 – Industry Symposium Sponsored by MSD K.K.

Plenary Hall | Room 203 | 2F

Refreshments will be provided

- 18:30 – 19:30** Chair: Takayasu Kurata, Japan
- 18:30 – 19:00** The Current Treatment and Future Perspective for Peri-operative NSCLC Treatment
Yasuhiro Tsutani, Japan
- 19:00 – 19:30** Latest Achievement in Metastatic NSCLC
Hiroaki Akamatsu, Japan

Program

SATURDAY | OCTOBER 29, 2022



Registration Desk Opening Hours: 07:00 – 13:15
Speaker Preview Center Opening Hours: 07:00 – 13:15

IS05 – Industry Symposium Sponsored by Novartis Pharma K.K.: Update Lung Cancer with Rare Deliver Mutation from Basic Research to Clinical Practice

Plenary Hall | Room 203 | 2F
Refreshments will be provided

- 07:30 – 08:30** Chair: Koichi Goto, Japan
- 07:30 – 07:32** Opening Remarks
Koichi Goto, Japan
- 07:32 – 07:57** Current and Future Perspectives on Molecular Diagnostics and Targeted Therapies for Non-small Cell Lung Cancer
Shingo Matsumoto, Japan
- 07:57 – 08:22** Current State of Targeted Therapy for Lung Cancer with Minor Driver Mutations and the Mechanism of Resistance
Seiji Yano, Japan
- 08:22 – 08:30** Q&A Session

PL03 – Evolving Landscape of Peri-Operative Therapy in NSCLC

Plenary Hall | Room 203 | 2F

- 08:45 – 10:15** Chairs: James Chih-Hsin Yang, Taiwan & Heather Wakelee, USA
- 08:45 – 08:47** Welcome and Introduction
- 08:47 – 09:03** PL03.01: Adjuvant Targeted Therapy
Masahiro Tsuboi, Japan
- 09:03 – 09:19** PL03.02: Adjuvant Immunotherapy
Caicun Zhou, China
- 09:19 – 09:35** PL03.03: Neoadjuvant Immunotherapy CheckMate816
Tetsuya Mitsudomi, Japan
- 09:35 – 09:51** PL03.05: Future Role of Surgeon in the Era of Immunotherapy
Paul Van Schil, Belgium
- 09:51 – 10:15** Q&A Discussion

10:15 – 10:45 Networking Break
 Exhibit Hall | Room 201+202 | 2F
Refreshments will be provided

ES11 – Therapeutic Progress of Mesothelioma and Thymic Neoplasm

Plenary Hall | Room 203 | 2F

- 10:45 – 11:45** Chairs: Steven Kao, Australia & Young Tae Kim, Republic of Korea
- Track: SCLC, Mesothelioma and Thymoma**
- 10:45 – 10:47** Welcome and Introduction
- 10:47 – 10:59** ES11.01: Molecular Subsets of Thymic Squamous Cell Carcinoma
Yosuke Yamada, Japan
- 10:59 – 11:11** ES11.02: Biomarkers and Novel Therapeutics in Mesothelioma
Anne Tsao, USA
- 11:11 – 11:23** ES11.03: Novel Combination of Immunotherapy in Mesothelioma
Steven Kao, Australia
- 11:23 – 11:35** ES11.04: Immunotherapy and Novel Treatment of Thymoma
Jinhyun Cho, Republic of Korea
- 11:35 – 11:45** Q&A Discussion

ES12 – Targeted Therapy

Breakout Room | Room 204 | 2F

- 10:45 – 11:45** Chairs: Dong Wan Kim, Republic of Korea & Misako Nagasaka, USA
- Track: Advanced / Metastatic NSCLC**
- 10:45 – 10:47** Welcome and Introduction
- 10:47 – 11:02** ES12.01: Targeting ALK as a Paradigm in Precision Oncology
Tony Mok, Hong Kong
- 11:02 – 11:17** ES12.02: Emerging ROS1 and RET Inhibitors and their Combinations
Thanyanan Baisamut, Thailand
- 11:17 – 11:32** ES12.03: Drugging the Undruggable: International Collaboration on Targeting KRAS G12C
Bob Li, USA
- 11:32 – 11:45** Q&A Discussion

IS06 – Industry Symposium Sponsored by Amgen K.K.: The Lung Cancer Treatment Landscape: Novel Targets and Treatment for Improved Patient Care

Breakout Room | Room 204 | 2F
Lunch will be provided

- 12:00 – 13:00** Chair: Tetsuya Mitsudomi, Japan
- 12:00 - 12:15** Biomarker Testing at Practice in East Asia
Yasushi Yatabe, Japan
- 12:15 - 12:30** KRAS G12C inhibitor Clinical Data
Bob Li, USA
- 12:30 - 13:00** Panel Discussion
Yasushi Yatabe, Japan, Bob Li, USA, Hidetoshi Hayashi, Japan

IS07 – Industry Symposium Sponsored by AstraZeneca K.K.: Adjuvant Therapy for EGFR Mutant Early-Stage NSCLC

Plenary Hall | Room 203 | 2F
Lunch will be provided

- 12:00 – 13:00** Chair: Hidehito Horinouchi, Japan
- 12:00 - 12:45** Current Status of Lung Cancer Perioperative Treatment
The Results of Clinical Trials which is Targeting EGFR Mutated NSCLC Patients, and Results of the ADAURA Study as a Recent Clinical Trial
Junko Tanizaki, Japan
- 12:45 - 13:00** Future Perspective for Perioperative Treatment Strategies by Prescribers

ES13 - Novel Targeted Therapies in Lung Cancer

Plenary Hall | Room 203 | 2F

- 13:15 – 14:15** Chairs: Tetsuya Mitsudomi, Japan & Kazuhiko Nakagawa, Japan
- Track: Advanced/Metastatic NSCLC**
- 13:15 – 13:17** Welcome and Introduction
- 13:17 – 13:30** ES13.01: ADC to TROP2 and CAECAM5
Byoung Chul Cho, Republic of Korea
- 13:30 – 13:43** ES13.02: Antibody Drug Conjugates to HER2 and HER3
Kazuhiko Nakagawa, Japan
- 13:43 – 13:56** ES13.03: Targeted Therapy for NRG1 Fusions and EGFR Exon 20 ins
James Chih-Hsin Yang, Taiwan
- 13:56 – 14:09** ES13.04: Met Targeting Agents
Noemí Reguart, Spain
- 14:09 – 14:15** Q&A Discussion

ES14 - Lineage Plasticity of Lung Cancer

Breakout Room | Room 204 | 2F

- 13:15 – 14:15** Chairs: Yasushi Yatabe, Japan & Chong-Jen Yu, Taiwan
- Track: Translational Science, Basic Science and Pathology**
- 13:15 – 13:17** Welcome and Introduction
- 13:17 – 13:29** ES14.01: Lineage Plasticity: SCLC Transformation as a Mechanism of Resistance
Triparna Sen, USA
- 13:29 – 13:41** ES14.02: Heterogeneity of Patient Outcome and Drug Response From a View of Histological Grade
Yoon-La Choi, Republic of Korea
- 13:41 – 13:53** ES14.03: Heterogeneity Between Primary and Metastatic Sites in Lung Cancer: Impacts From Morphology Versus Genomics/Immune Environment
Teh-Ying Chou, Taiwan
- 13:53 – 14:05** ES14.04: Identifying a Tissue Stem Cell Subpopulation by Combining Single-Cell Mor-Phometrics, Organoid Culture, and Transcriptomics
Mitsuru Morimoto, Japan
- 14:05 – 14:15** Q&A Discussion

IASLC



2023 Targeted Therapies of Lung Cancer Meeting

FEBRUARY 22-25, 2023 | SANTA MONICA, CALIFORNIA

**SAVE
THE
DATE**


The **2023 Targeted Therapies of Lung Cancer Meeting** will highlight information about ongoing clinical trials of the newest therapies for lung cancer including data on preclinical and early clinical trials.

#TTLC23

For more information visit ttlc2023.iaslc.org

05

Poster Sessions



#ACLC22



Poster Sessions

THURSDAY | OCTOBER 27, 2022

Exhibit Hall, Room 201+202, 2F

Posters on Display:

Thursday, October 27 - 10:00 until

Saturday, October 29 - 13:30

Author Availability/Stand by Time:

Thursday, October 27 - 18:00 - 19:00

Poster Tour 1

18:00 - 19:00

- Discussant** Chong-Jen Yu, Taiwan will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.
Delegates are invited to join the Poster Tour.
- PPT01.01** **Protein Changes during Immune-Related Adverse Events and Corticosteroid Treatment in Cancer Patients Receiving Immune Checkpoint Inhibitors**
Hiroaki Kanemura, Japan
- PPT01.02** **Study on Tumor Immune Microenvironment of Pulmonary Lymphoepithelial Carcinoma Using Multiplex Immunohistochemical Staining**
Wei-Hsun Hsu, Taiwan

Poster Tour 2

18:00 - 19:00

- Discussant** Sita Andarini, Indonesia will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.
Delegates are invited to join the Poster Tour.
- PPT02.01** **Risk of Thromboembolism in NSCLC with Different Oncogenic Drivers, Including ROS1, ALK and EGFR Mutation**
Hsin-Yi Wang, Taiwan
- PPT02.02** **Computer-Assisted Flagging of Never Smokers at High Risk of NSCLC in a Large US-Based HMO Using the LungFlag Model**
Eran Netanel Choman, Israel
- PPT02.03** **Preoperative Localization Technique using Mixture of Indigo-Carmine and Lipiodol of Pulmonary Nodule via Transbronchial Approach**
Soojin Lee, Republic of Korea
- PPT02.04** **Analysis of Pre-Analytic Factors Affecting the Success of Next-Generation Sequencing of Non-Small Cell Lung Cancer**
Naoki Shiraishi, Japan

Poster Sessions

With Presenters Available for Questions

18:00 - 19:00

Advanced/Metastatic NSCLC - Immunotherapy

- PP01.01** **A Meta-Analysis for Treatment-Related Adverse Events of Combination Chemoimmunotherapy vs Chemotherapy in First-Line Treatment for NSCLC**
Kazuki Takada, Japan
- PP01.02** **Central Nervous Systemic Efficacy of Immune Checkpoint Inhibitors and Concordance Between Intra/extra-cranial Response in Non-small Cell Lung Cancer Patients with Brain Metastasis**
Sora Kang, Republic of Korea
- PP01.03** **Effectiveness of Adding Chemotherapy to ICI for First-Line Treatment of Advanced NSCLC with PD-L1 Score Around 50%: Regression Discontinuity Analysis**
Yuji Uehara, Japan
- PP01.04** **Association of Thyroid Transcription Factor-1 with the Efficacy of Immune-Checkpoint Inhibitors in Patients with Advanced Lung Adenocarcinoma**
Kenji Nakahama, Japan
- PP01.06** **Efficacy and Safety of Immune Checkpoint Inhibitors with Chemotherapy for Patients of Performance Status 2 with Advanced NSCLC**
Hirohisa Kano, Japan
- PP01.07** **Prognostic Factor of TTF-1 Expression for Lung Adenocarcinoma Patients Received Chemotherapy Plus Immune Checkpoint Inhibitor**
Reina Goshono, Japan
- PP01.08** **Analysis of the Effect of Mediastinal Lymph Node Dissection on the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer**
Yohei Kawaguchi, Japan
- PP01.09** **Analyses of the Outcome of Immune Checkpoint Inhibitors for Postoperative Recurrent Disease in NSCLC**
Takafumi Hashimoto, Japan
- PP01.10** **Long-Term Progression-Free Survival after Discontinuation of Immune Checkpoint Inhibitors**
Taiyo Nakamura, Japan

Advanced/Metastatic NSCLC - Targeted Therapy

- PP01.11** Success of Tepotinib Therapy in Overcoming Resistance to Osimertinib in a Patient with EGFR-Mutant Lung Adenocarcinoma With a Potential Acquired MET Exon 14 Skipping Mutation
Shinkichi Takamori, Japan
- PP01.12** A Project to Investigate the Actual Status of Biomarker Testing in Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer: WJOG15421 L (REVEAL)
Toshihide Yokoyama, Japan
- PP01.13** Efficacy and Intracranial Activity of Tepotinib in Japanese Patients with MET Exon 14 Skipping NSCLC (VISION)
Masahiro Morise, Japan
- PP01.14** Tepotinib in Asian Patients with Advanced NSCLC with MET Exon 14 (METex14) Skipping
Terufumi Kato, Japan
- PP01.16** Resistance Mechanisms to Osimertinib in Advanced EGFR-Mutated NSCLC: An Update from a Single Institution Prospective Cohort Study
Bin-Chi Liao, Taiwan
- PP01.17** Phase 1/2a Study Evaluating Alecinib Pharmacokinetics and Efficacy in Hispanic Population with Advanced ALK-rearranged Non-small Cell Lung Cancer
Oscar Arrieta, Mexico
- PP01.18** Clinical Outcomes for EGFR and HER2 Exon 20 Insertion-Mutated Advanced Lung Cancer
Kelly Li, Canada
- PP01.19** Overall Survival Benefits of First-Line Treatments for Asian Patients with Advanced Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Harboring Exon 19 Deletion: A Systematic Review and Network Meta-Analysis
Sik-Kwan Chan, Hong Kong
- PP01.20** Prevalence of Central Nervous System Metastasis in EGFR Mutated Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study
Archana Supavavej, Thailand
- PP01.21** Clinical Characteristics and Real-World Progression-Free Survival of Patients with EGFR Mutation-Positive Adenocarcinoma Lung Cancer Treated with EGFR as the First Line: A Retrospective Cohort Study from Indonesia
Noni Novisari Soeroso, Indonesia
- PP01.22** The Detection Rate of EGFR Gene Mutations in the Cobas EGFR Mutation Test and the Oncomine Dx Target Test Multi-CDx System in Our Hospital
Masahide Ota, Japan

- PP01.23** Differences in First Generation EGFR-TKI Responses in Advanced Stage Lung Adenocarcinoma with EGFR Mutations
Uun Unaedi, Indonesia
- PP01.24** Survival Difference of EGFR Exon 19 Deletion and Exon 21 Mutation in Asian Patients with Advanced Non-small Cell Lung Cancer
Dawn Lynn Guardiaro, Philippines

Translational Science, Pathology and Basic Science

- PP01.26** Impact of AXL Expression on the Efficacy of Osimertinib in Untreated EGFR-Mutated NSCLC
Tadaaki Yamada, Japan
- PP01.27** Exploration of Secondary Resistant Mutations Against Mobocertinib - in Vitro Study with Various EGFR Exon 20 Insertion Models
Akira Hamada, Japan
- PP01.28** The Utility of the Anti-CKAP4 Monoclonal Antibody in DKK1-CKAP4 Signal-Activated Lung Cancer
Akihiro Nagoya, Japan
- PP01.30** MiR-503 Pleiotropically Regulates Epithelial-Mesenchymal Transition and Targets PTK7 to Control Lung Cancer Metastasis
Tzu-Hsiu Tsai, Taiwan
- PP01.31** Programmed Death-Ligand 1 Promotes Chemotaxis in EGFR-Mutant Non-Small Cell Lung Cancer through Regulating Cytokine Expression
Chia-Chi Hsu, Taiwan
- PP01.32** Activation of EIF2 Signaling and HIF-1 α Signaling as Possible Mechanisms of NSCLC Tumor Cell Proliferation Through Induction of Autophagy
Ferdinand Mira, Philippines
- PP01.33** Clinical and Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors
Shang-Gin Wu, Taiwan
- PP01.34** ACTN4 is Related to the Migration and Proliferation of Thymic Cancer Through β -catenin Pathway
Hideki Nagata, Japan
- PP01.35** Dysregulation of Lipid Metabolism Leads to Resistance of Lung Cancer Stem Cells to Reactive Oxygen Species-Induced Cell Death
Han-shui Hsu, Taiwan
- PP01.37** Dynamic Alteration of Peripheral Immune Cells in Patients with NSCLC Received Anti-PD-1/PD-L1 Therapy and Clinical Efficacy
Naruo Yoshimura, Japan
- PP01.38** Cyclooxygenase-2 Expression Level in Primary Tumors is Associated with Vasculogenic Mimicry Formation and Survival in T1 Lung Adenocarcinoma
Ming-Wei Kao, Taiwan

- PP01.39** Expression of Cluster Differentiation 109 Promotes Tumorigenesis and Is Associated with an Adaptive Immune Resistance in Lung Adenocarcinoma
Chengwei Lin, Taiwan
- PP01.41** Immunohistochemistry Techniques to Differentiate Adenocarcinoma or Squamous Cell Lung Cancer
Linda Masniari, Indonesia
- PP01.42** Diagnosis of MET Gene Alterations in Advanced NSCLC with Next Generation Sequencing
Nguyen Son Lam, Vietnam

Poster Sessions

FRIDAY | OCTOBER 28, 2022

Exhibit Hall, Room 201+202, 2F

Posters on Display:

Thursday, October 27 - 10:00 until

Saturday, October 29 - 13:30

Author Availability/Stand by Time:

Friday, October 28 - 17:00 - 18:30

Poster Tour 3

17:00 - 18:30

- Discussant** Keunchil Park, Republic of Korea will be facilitating a Poster Tour and discuss the following posters with the presenters at their posters in the Exhibit Hall.
Delegates are invited to join the Poster Tour.
- PPT03.01** **Phase II Study of S-1 and Cisplatin with Concurrent Thoracic Radiotherapy Followed by Durvalumab for Unresectable, Locally Advanced Non-Small-Cell Lung Cancer in Japan (SAMURAI Study)**
Kazuhiko Shibata, Japan
- PPT03.03** **Prognosis and Efficacy of Adjuvant Therapy in Post-Surgical NSCLC Patients with WES Based Genetic Profiling**
Akiko Tateishi, Japan
- PPT03.04** **AI-based Quantitative CT Analysis for Prediction of Radiation Pneumonitis after Stereotactic Body Radiotherapy for the Lung**
Masahiro Yoneyama, Japan
- PPT03.05** **Afatinib + Bevacizumab vs Afatinib Alone as First Line Treatment of Patients with EGFR Mutated NSCLC: Subgroup Analysis of a Randomized, Phase II Study: AfaBev-CS**
Toshiyuki Kozuki, Japan
- PPT03.06** **The Case Fatality Rate of COVID-19 Infection and Effect on Systemic Treatment of COVID-19 Infection in Non-Small Cell Lung Cancer**
Yeji Jung, Republic of Korea

Poster Sessions

With Presenters Available for Questions

17:00 - 18:30

Diagnosis, Imaging and Bronchoscopy

- PP02.01** **Role of Bronchoscopy for Lung Cancer Diagnosis in Elderly Patients**
Hye-rin Kang, Republic of Korea
- PP02.02** **Respiratory Sarcopenia Predicts Postoperative Outcomes in Patients with Non-Small Cell Lung Cancer**
Yoshifumi Hirata, Japan
- PP02.03** **Shared Presurgical Understanding for Lung Cancer in Patient's Acquaintances Using CT-Derived 3D Virtual Explanation Module**
Kwon Joong Na, Republic of Korea

- PP02.04** **Multiple Non-Small Cell Lung Cancers Including One Tumor with EGFR Mutation and Another Without That**
Taisuke Matsubara, Japan
- PP02.05** **Postoperative Pleuroparenchymal Fibroelastosis (PPFE) like Ipsilateral Upper Lung Field Pulmonary Fibrosis, Differentiation from the Lung Cancer Recurrence**
Takao Nakanishi, Japan
- PP02.06** **Primary Pure Signet-Ring Cell Carcinoma of Lung with ALK Rearrangement - Case Report**
Akira Okimura, Japan
- PP02.07** **Pilot Study for Early Diagnosis of Lung Cancer in a Public Hospital in Northeast Brazil**
Carlos De Araújo, Brazil
- PP02.08** **The Usefulness of Liquid Biopsy When Biopsy Not Feasible in a Patient of EGFR Positive Non-Small Cell Lung Cancer (NSCLC), a Case Report**
Yeongha Ryu, Republic of Korea
- PP02.09** **A Long Term Follow-Up of Papillary Thyroid Carcinoma Arising in Mature Cystic Mediastinal Teratoma**
Ananda Febriani Aulia, Indonesia

Early Stage NSCLC

- PP02.10** **Perioperative Electrolyte Levels and Postoperative Atrial Fibrillation Following Robotic-Assisted Pulmonary Lobectomy**
Lauren Ladehoff, USA
- PP02.11** **Effect of PM2.5 on Tumor Recurrence, Mortality, and Postoperative Complications in Resectable Non-Small Cell Lung Carcinoma: A Retrospective Cohort Study**
Sophon Siwachat, Thailand
- PP02.12** **A Trans-omics Assessment of Gene-gene Interaction in Early Stage NSCLC**
Li Su, USA
- PP02.13** **Comparison Between Lobectomy and Proton Therapy for Confirmed Stage I Lung Cancer**
Tadashi Sakane, Japan
- PP02.14** **Prognostic Impact of Ground Glass Opacity Component and Consolidation Size in Clinical Stage IA Lung Adenocarcinoma After Sublobar Resection: A Quantitative Analysis**
Jae Kwang Yun, Republic of Korea
- PP02.15** **Long-Term Results of Transbronchial ICG Administration in Limited Surgery for Early Stage Lung Cancer**
Yasuo Sekine, Japan

- PP02.16** Correlation of SUVmax of Primary Lung Tumor and Occult Lymph Node Metastases in Clinical Stage I Lung Adenocarcinoma
Kenichi Suda, Japan
- PP02.17** Challenges of the Eighth Edition of the American Joint Committee on Cancer Staging System for Pathologists Focusing on Early-Stage Lung Adenocarcinoma
Shiu-feng Huang, Taiwan
- PP02.18** Effects of Insurance Type and Distance from the Cancer Center on Outcomes after Robotic-Assisted Pulmonary Lobectomy
Allison Dumitriu Carcoana, USA
- PP02.19** Impact of Preoperative Cardiovascular Comorbidities on Perioperative Outcomes After Robotic-Assisted Pulmonary Lobectomy
Jenna Marek, USA
- PP02.20** Postoperative Atrial Fibrillation Propensity After Robotic-Assisted Pulmonary Lobectomy by Number of Segments
Cole Fiedler, USA
- PP02.21** Impact of the COVID-19 Pandemic on Perioperative Outcomes after Robotic-Assisted Pulmonary Lobectomy
William Doyle, USA
- PP02.22** Effect of Gender on Incidences of Peri-Operative Complications after Robotic-Assisted Video-Thoroscopic Pulmonary Lobectomy
Kristie Labib, USA
- PP02.23** Effects of Perioperative Potassium Levels on Incidence of Postoperative Complications Following Robotic-Assisted Pulmonary Lobectomy
Lauren Ladehoff, USA
- PP02.24** Adenocarcinoma In Situ Manifesting as a Part Solid Nodule with High CTR: Radiologic and Pathologic Characteristics
Emi Hagui, Japan
- PP02.25** Fibroblast Activation Protein Expression in the Alveolar Structures of Patients with Lung Adenocarcinomas
Toru Kimura, Japan
- PP02.26** Selection of Surgery Focusing on Lymph Node Dissection: Robot-Assisted Surgery or Single Port Thoracoscopic Surgery?
Yuki Yagi, Japan
- PP02.27** Treatment Outcomes of Surgery and SBRT for Early Lung Cancer
Chi Young Kim, Republic of Korea
- PP02.29** Dynamic Change of Immune Repertoire Profiling in Stage III Non-Small Cell Lung Cancer (NSCLC) Patients During Consolidation Treatment With Immunotherapy
Dulyathat Anantaya, Thailand
- PP02.30** Normalization of Tumor Marker Value Predicts Better Prognosis in Patients with Unresectable Stage III NSCLC
Momoko Morishita, Japan
- PP02.31** MMP3, Fractalkine and MIF are Associated with Clinical Outcomes in Locally Advanced NSCLC Treated with Chemoradiotherapy and Durvalumab
Yoshiro Nakahara, Japan
- PP02.32** A Phase II Trial of Biweekly Carboplatin and Nab-Paclitaxel with Concurrent Radiotherapy for Patients with Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer: Long Follow up Survival Data
Hisashi Tanaka, Japan
- PP02.33** Peripheral Blood Markers Correlate with Pathological Complete Response and Prognosis in Resectable NSCLC Patients Treated with Neoadjuvant Chemoimmunotherapy
Yan Hu, China
- PP02.34** Feasibility of Hypo-Fractionated Radiotherapy (55 Gy/20 Fractions) in NACT Unresponsive and Co-Morbid Patients of NSCLC
Anupam Datta, India
- PP02.35** Locally Advanced Non-Small Cell Lung Carcinoma as a Non-Mucinous Adenocarcinoma in a 15-Year-Old Child: A Rare Presentation
Vijay Kumar, India
- PP02.36** Pulmonary Carcinosarcoma: A Report Case from Vietnam
Linh Le Tu, Vietnam
- Palliative and Supportive Care**
- PP02.37** Affected Quality of Life and Burden of Lung Symptoms in Patients with Suspected Lung Cancer: A Prospective Longitudinal Study
Narongwit Nakwan, Thailand
- PP02.38** The Great Survival Benefit from Ma Recipe Therapeutics for Patients with Advanced Lung Cancer: A Retrospective Study
Jiangnan Feng, China
- PP02.39** Hippocampal Avoidance Whole Brain Radiotherapy with Simultaneous Integrated Boost – An Alternative to Stereotactic Radiosurgery?
Anil Tibdewal, India
- Locally Advanced NSCLC**
- PP02.28** Analysis of PD-L1 Negative Subgroups in Real World Survey (CRIMSON) of Definitive Chemoradiotherapy in Locally Advanced NSCLC
Hayato Kawachi, Japan

Risk Reduction, Early Detection, Epidemiology and Tobacco Control

- PP02.40** Electronic Cigarettes Use and 'Dual-Use' Among the Youth in 75 Countries - Estimates from Global Youth Tobacco Surveys (2014-2019)
Chandrashekhara Sreeramareddy, Malaysia
- PP02.41** Role of Preoperative Inhalation Therapy for Lung Cancer Patients with Chronic Obstructive Pulmonary Disease
Yasushi Shintani, Japan
- PP02.42** Clinical Significance of the TTR / RBP Ratio in Patients Undergoing Surgery for Lung Cancer
Jun Suzuki, Japan
- PP02.43** Impact of a Multidisciplinary Team Conference on Non-Small Cell Lung Cancer Care: Time Barriers and Long-Term Outcomes
Apichat Tantraworasin, Thailand
- PP02.44** Relationship Between Worsening Postoperative Dyspnea and Preoperative Respiratory Function
Takuya Ohashi, Japan
- PP02.45** An Investigation on Inflammatory and Oncological Biomarkers in Lung Cancer Diagnosis: A Data-Driven Approach
Mohammad Tanvir Ahamed, Sweden
- PP02.46** Sublobar Resection Might Be Effective Option for Lung Cancer Patients on Dialysis
Hiroki Matsumoto, Japan
- ## SCLC, Mesothelioma, Thymoma
- PP02.47** Two Cases of Sarcomatoid Mesothelioma from Mesothelioma In Situ
Naoe Jimbo, Japan
- PP02.48** Semi-Rigid Thoracoscopy using Small Forceps; a Promising Diagnostic Method for Malignant Pleural Mesothelioma
Yun Seok Kim, Republic of Korea
- PP02.49** Paraneoplastic Neurological Syndrome in Small Cell Lung Cancer
Takayo Ota, Japan
- PP02.50** A Real-World Study on the Efficacy and Safety of PD-L1 inhibitor Plus Platinum-Etoposide Chemotherapy in Patients with Extensive Stage SCLC: A Prospective Observational Study
Kenji Morimoto, Japan
- PP02.51** Life Expectancy after Discontinuation of Chemotherapy in Patients with Small Cell Lung Cancer
Kazushi Yoshida, Japan
- PP02.52** Clinical Profile, Prognostic Factors, and Treatment Outcomes in Patients of Thymoma: A Decade of Experience from a Single Centre
Divya Khosla, India
- PP02.53** Neuro-Cognitive Effect of WB-PCI in LS-SCLC
Suryakanta Acharya, India
- PP02.54** Experience in the Treatment of Patients with Advanced Thymic Cancer
Yuki Akazawa, Japan



VIRTUAL POSTERS ONLY

- PV01.01** Individualized Prediction of Survival Benefit from Postoperative Radiotherapy for Patients with Malignant Pleural Mesothelioma
Yang Wo, China
- PV01.02** Experience of Cyto-reductive Surgery and Intra-Operation Adjuvant Therapy for Malignant Pleural Mesothelioma at a Single Center in Taiwan
Yei San Hsieh, Taiwan
- PV01.03** A Phase I Trial of the HER2 TKI, BI 1810631, in Patients with Advanced Solid Tumors with HER2 Aberrations
Noboru Yamamoto, Japan
- PV01.04** Clinical Trials During Covid Pandemic - The Show Must Go On
Mansi Sharma, India
- PV01.05:** Efficacy of Immunotherapy in Second-Line Treatment of KRAS Mutated Patients with Non-Small Cell Lung Cancer - Data from Daily Practice
Magdalena Knetki-Wróblewska, Poland
- PV01.06** The Value of Next-Generation Sequencing in the Differential Diagnosis of Mediastinal Tumor (Case Report)
Magdalena Knetki-Wróblewska, Poland
- PV01.07** Predictors of Psychological Distress in Informal Caregivers of Patients after Surgical Treatment of Early-Stage Lung Cancer
Song Zhu, China
- PV01.08** Liquid Biopsy-Based Fragmentomic Assay for Malignancy Classification of Radiographically Highly Suspicious Lung Nodules
Rong Yin, China
- PV01.09** Electronic Cigarettes Use and 'Dual-Use' Among the Youth in 75 Countries - Estimates from Global Youth Tobacco Surveys (2014-2019)
Chandrashekhara Sreeramareddy, Malaysia
- PV01.10** Modulating EGFR TKI Resistance by Dosage and Timing
Jo Monsen, Norway
- PV01.11** Unique Molecular Properties of East Asian EGFR-Mutant Non-Small Cell Lung Cancer Patients at Early and Advanced Stages: K-MASTER Project
Yoon Ji Choi, Republic of Korea
- PV01.12** Comparison of Adjuvant Osimertinib, 1st TKIs, Chemo-TKI, Immunotherapy and Chemotherapy for Resected EGFR-Mutant NSCLC - an Updated Network Meta-Analysis of 3300 Patients
Guang-Ling Jie, China



2023 World Conference on Lung Cancer

SEPTEMBER 9-12, 2023 | SINGAPORE

Save the Date!

Join us for WCLC 2023 in Singapore!

Abstract Submissions will open in January 2023.

Showcase your research and contribute to discussions that will shape the future of treatments in lung cancer and thoracic malignancies.

CONNECT WITH US

 @IASLC

 facebook.com/IASLC

 @iaslungcancer

 linkedin.com/IASLC

 IASLC

#WCLC23
WCLC2023.IASLC.org

06

Education Awards



#ACLC22



Education Awards

Congratulations to the following ACLC 2022 Education Award Winners!

Award Winners will be presented with their awards during Plenary 2 on **Friday, October 28** from **08:45 – 10:15**.

Wonyoung Jung, Republic of Korea

OA02.05: Fear of Cancer Recurrence and its Predictors among Patients with Non-Small Cell Lung Cancer (NSCLC)

OA02 - Oral Abstract Session 2, Friday, October 28 13:15 – 14:30

Alvaro Quintanal-Villalonga, USA

OA02.03: AKT Pathway as a Therapeutic Target to Constrain Lineage Plasticity Leading to Histological Transdifferentiation

OA02 - Oral Abstract Session 2, Friday, October 28 13:15 – 14:30

Prerna Gautam, India

OA01.02: Operational Management Challenges in Continuing Lung Cancer Screening during COVID-19 Pandemic

OA01 - Oral Abstract Session 1, Thursday, October 27 17:00 – 18:00

Tadashi Sakane, Japan

PP02.13: Comparison Between Lobectomy and Proton Therapy for Confirmed Stage I Lung Cancer

Poster Viewing Reception B, Friday, October 28 17:00 – 18:30

Sora Kang, Republic of Korea

PP01.02: Central Nervous Systemic Efficacy of Immune Checkpoint Inhibitors and Concordance Between Intra/extracranial Response in Non-small Cell Lung Cancer Patients with Brain Metastasis

Poster Viewing Reception A, Thursday, October 27 18:00 – 19:00

Yang Wo, China

PV01.01: Individualized Prediction of Survival Benefit from Postoperative Radiotherapy for Patients with Malignant Pleural Mesothelioma

Virtual Poster

Guang-Ling Jie, China

PPT03.02: Comparison of Adjuvant Osimertinib, 1st TKIs, Chemo-TKI, Immunotherapy and Chemotherapy for Resected EGFR-Mutant NSCLC – an Updated Network Meta-Analysis of 3300 Patients

Poster Tour 3, Friday, October 28 17:00 – 18:30

07

Abstract Author Index



#ACLC22



Abstract Author Index

A

Abe, Miyuki PP01.09
 Acharya, Kiran PP02.40
 Acharya, Suryakanta PP02.53
 Adachi, Taishi PP02.05
 Adachi, Tetsuya PP01.37
 Agarwal, Jai Prakash PP02.39
 Ahamed, Mohammad Tanvir PP02.45
 Ahmadin, Herudian PP01.23
 Ahn, Jin Seok PPT02.06
 Ahn, Mi Sun PP01.29
 Ahn, Myung-Ju PPT02.06, PP01.14
 Akamatsu, Hiroaki PP01.12
 Akazawa, Takashi PP02.25
 Akazawa, Yuki PP02.54
 Allaj, Viola OA02.03
 Amano, Yoshihiro PPT02.04
 Ameku, Koken PP02.54
 Anantaya, Dulyathat PP02.29
 Andersson, Björn PP02.45
 Ando, Chihiro PP01.06
 Anraku, Masaki PP02.02
 Aoe, Keisuke PPT02.04
 Aoki, Masahiko PP02.32
 Aoki, Takuya PP01.08, PP01.10
 Arai, Daisuke PP02.28
 Arce, Jayson PP01.32
 Arrieta, Oscar PP01.17
 Asai, Kazuhisa PP01.04
 Atagi, Shinji PP01.13
 Atobe, Yuri PP01.37
 Aulia, Ananda Febriani PP02.09
 Azuma, Koichi OA01.05

B

Baba, Yuri PP02.51
 Bae, Suk-Chul PP01.15
 Bahl, Amit PP02.52
 Baldonado, Jobelle PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
 Bao, Hua PV01.08
 Batra, Ullas PV01.04
 Beginta, Romi PP01.41
 Benjawongsathien, Duangnapa PP01.20
 Berghoff, Karin PP01.14
 Bessho, Akihiro PP01.06, PPT02.04
 Bhanot, Umesh OA02.03
 Bhattacharya, Jibak PP02.34
 Bhogadi, Amani PP02.39
 Bosdet, Ian PP01.18
 Bowornkitiwong, Thipawan PP01.20
 Bruns, Rolf PP01.13, PP01.14
 Burkard, Mark E. OA02.06

C

Camidge, D Ross OA02.06
 Carrizosa, Daniel R. OA02.06
 Chakrabarty, Nivedita PP02.39
 Chan, Sik-Kwan PP01.19
 Chang, Il-Chi PP02.17
 Chang, Tzu-Hua PP01.30
 Chang, Yih-Leong PPT01.02
 Chang, Yoon Soo PP02.27
 Chantharakhit, Chaichana PP01.20
 Chantratita, Wasun PP02.29
 Chao, Yi-Chun PP01.39
 Charoentum, Chaicut PP02.43
 Charoenyingwattana, Angkana PP02.29
 Chayangsu, Chawalit PP01.20
 Cheema, Parneet K. OA02.06
 Chen, Chih-Yi PP02.17
 Chen, Chung-Yu PPT01.04

Chen, Feng PP02.12
 Chen, Hsiu-Hsi OA01.01
 Chen, Jiajin PP02.12
 Chen, Kuan-Yu OA02.02
 Chen, Shihao PV01.07
 Chen, Yen-lin OA02.02
 Chen, Yuh-Min PP01.14
 Chen, Zhi-Hong PPT02.02
 Chen, Zhiwei OA02.04
 Chewaskulyong, Busayamas PP02.11
 Chewaskulyong, Busayamas PP02.43
 Chiba, Masato PP01.27, PP02.16
 Chiba, Yasutaka OA01.05
 Chihara, Yusuke PP01.26, PP02.49
 Chikamori, Kenichi PP01.13
 Cho, Byoung Chul PP01.29
 Cho, Jang Ho PP01.29
 Cho, Juhee OA02.05
 Cho, Sung Shim PP01.29
 Choi, Chang Min PP01.02
 Choi, Daeho PPT02.06
 Choi, Horace Cheuk-Wai PP01.19
 Choi, Yoon Ji PP01.29
 Choman, Eran Netanel PPT01.05
 Christiani, David C PP02.12
 Chung, Hee-Joon PP01.29
 Ciampricotti, Metamia OA02.03
 Cornelio, Gerardo Tomas PP01.24
 Cruz-Rico, Graciela PP01.17

D

Daga, Haruko OA01.05
 Date, Koji PP02.49
 Datta, Anupam PP02.34
 De Araujo, Carlos PP02.07
 Desai, Jayesh OA02.06
 Dimayacac-Esleta, Baby Rorielyn PP01.32
 Domen, Hiromitsu PP02.26
 Dong, Song PPT02.02
 Doyle, William PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
 Drilon, Alexander OA02.06
 Dumitriu Carcoana, Allison PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23

d

de Stanchina, Elisa OA02.03

E

Egger, Jacklynn OA02.03
 Eggleton, S Peter PP01.13
 Elamin, Yasir Y. OA02.06
 Eom, Jung Seop PPT01.07
 Eriguchi, Daisuke PP02.06
 Eriksson, Lars E PP02.45
 Euathrongchit, Juntima PP02.43

F

F. Cardona, Andrés PP01.17
 Feng, Jiangnan PP02.38
 Feng, Xue PP02.38
 Fiedler, Cole PP02.20, PP02.22, PP02.23
 Fontaine, Jacques PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
 Fujii, Tomomi PP01.22
 Fujimoto, Junya PP01.12
 Fujimoto, Nobukazu PP01.06, PPT02.04
 Fujitaka, Kazunori PPT02.04
 Fujiwara, Ayako PP02.41
 Fujiwara, Keiichi PP01.06, PPT02.01
 Fukai, Mari PP02.54
 Fukuda, Akito PP01.26

Fukuda, Shota PP01.27, PP02.16
 Fukuda, Yasushi PP02.28
 Fukui, Eriko PP01.28, PP01.34
 Fukui, Shin PP01.07
 Fukuoka, Kazuya PPT01.08
 Fukuoka, Masahiro PP02.49
 Fumita, Soichi PPT01.01
 Funaki, Soichiro PP01.28, PP01.34
 Furukawa, Kinya PP02.04
 Fusamoto, Aya PP02.44

G

Gadgeel, Shirish M. OA02.06
 Gao, Meiyang PP02.38
 García-López, Patricia PP01.17
 Garrett, Joseph PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
 Gautam, Prerna OA01.02
 Goo, Jin Mo PP02.03
 Goshono, Reina PP01.07
 Goto, Yasuhiro PP01.26
 Goto, Yasushi PP02.30
 Gow, Chien-Hung PP01.30
 Guardiario, Dawn Lynn PP01.24
 Guo, Tiantian OA01.04

H

Ha, Jick Hwan PP02.48
 Hagui, Emi PP02.13, PP02.24
 Hakozaki, Taiki PP01.03
 Hamada, Akira PP01.27, PP02.16
 Hamada, Yukihiko PP02.49
 Hamamoto, Ryuji PPT01.03
 Han, Ji-Youn PP01.14
 Handa, Tomohiro PPT02.03
 Haneda, Hiroshi PP02.13
 Hara, Satoshi PP02.28
 Harada, Taishi PP01.26, PP02.49
 Haratani, Koji PPT01.01
 Harrup, Rosemary OA02.06
 Hashimoto, Kazuki PP02.54
 Hashimoto, Takafumi PP01.09
 Hashinokuchi, Asato PP01.11
 Hata, Akito OA01.05
 Hata, Atsushi PP02.46
 Hatayama, Yoshiomi PP02.32
 Hattori, Yukiko PP02.13
 Haura, Eric B. OA02.06
 Hayashi, Hidetoshi OA01.05, PPT01.08, PPT01.01
 Hayashi, Mariko PP02.26
 Heredia, David PP01.17
 Hernández-Pedro, Norma PP01.17
 Hida, Yasuhiro PP02.26
 Himuro, Hidetomo PP02.31
 Hirai, Toyohiro PPT02.03
 Hirai, Yoshimitsu PP02.44
 Hirano, Hiroshi PP02.06
 Hiranuma, Osamu PP01.26
 Hiraoka, Manabu PP01.12
 Hirata, Yoshifumi PP02.02
 Ho, Chao-chi PP01.16
 Ho, Cheryl PP01.18
 Hong, Tse-Ming PP01.38
 Honma, Keiichiro PP02.25
 Hontsu, Shigeto PP01.22
 Horinouchi, Hidehito PPT01.03, PP02.30
 Hoshino, Hidehisa PP02.15
 Hosoda, Chiaki PP02.51
 Hosomi, Yukio PP01.03
 Hotta, Katsuyuki PP01.06
 Houck-Loomis, Brian OA02.03
 Hsegawa, Yukihiro PP02.32
 Hsia, Jiun-Yi PP02.17

Hsieh, Min-Shu	PP01.30, PPT01.02	Kang, Lu	PV01.07	Kuwano, Kazuyoshi	PP02.51
Hsieh, Yei San	PV01.02	Kang, Sora	PP01.02	Kuyama, Shoichi	PPT02.04
Hsu, Chia-Chi	PP01.31, PPT01.02	Kankanopas, Thagoon	PP02.37	Kwang Chae, Young	OA02.06
Hsu, Han-shui	PP01.35	Kano, Hirohisa	PP01.06		
Hsu, Wei-Hsun	PP01.31, PPT01.02	Kanou, Takashi	PP01.28, PP01.34	L	
Hu, Yan	PP02.33	Kao, Ming-Wei	PP01.38	Labib, Kristie	PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
Huang, Derek De-Rui	PPT01.02	Kapoor, Rakesh	PP02.52	Ladehoff, Lauren	PP02.22, PP02.23
Huang, Jason	PP01.14	Karashima, Takashi	PP01.09	Lam, Nguyen Son	PP01.42
Huang, Jei-Yie	OA02.02	Kato, Hiroaki	PP01.08, PP02.06	Lanyado, Alon	PPT01.05
Huang, Shiu-feng	PP02.17	Kato, Terufumi	PP01.13, PP01.14	Lara-Mejía, Luis	PP01.17
Huang, Yen-Lin	PP01.33	Kawachi, Hayato	PP02.28	Laskin, Janessa	PP01.18
Hung, Shih-Chieh	PP01.35	Kawaguchi, Tomoya	PP01.04	Le, Xiuning	PP01.14
		Kawaguchi, Yohei	PP01.08, PP01.10, PP02.06	Le Tu, Linh	PP02.36
I		Kawai, Haruyuki	PP01.06	Lee, Dae Ho	PP01.02
Ichihara, Eiki	PP01.06	Kawakami, Hisato	PPT01.01	Lee, Eun Hye	PP02.27
Ichikawa, Akihiro	PP02.51	Kawanaka, Yusuke	PPT01.08, PPT01.01	Lee, Genehee	OA02.05
Ichikawa, Hirohisa	PP01.06, PPT02.04	Kenmotsu, Hirotosugu	PP01.26, PP01.12	Lee, Jae Cheol	PPT01.02
Ichinokawa, Kazuomi	PP02.26	Ketpueak, Thanika	PP02.43	Lee, Jih-Hsiang	PPT01.02
lemwimangsa, Nareenart	PP02.29	Khiewngam, Khantong	PP02.29	Lee, Kang-Yun	PP01.39
Igaki, Hiroshi	PPT01.03	Khosla, Divya	PP02.52	Lee, Na Hyeon	PPT01.07
Iguchi, Hideto	PP02.44	Kikuchi, Akira	PP01.28	Lee, Se-Hoon	PPT02.06
Ikeda, Naoki	PP02.41	Kikuchi, Mio	PP01.07	Lee, Soojin	PPT01.07
Ikeda, Norihiko	PP02.04	Kim, Beong Ki	PP02.27	Lee, Victor Ho-Fun	PP01.19
Ikeda, Satoshi	OA01.05	Kim, Chi Young	PP02.27	Lertprasertsuke, Nirush	PP02.43
Im, Somin	OA01.03	Kim, Eun Young	PP02.27	Levitsky, Adrian	PP02.45
Imai, Kentaro	PP01.08, PP01.10, PP02.06	Kim, Ho Sung	PP01.02	Li, Baiyong	OA02.04
Inaba, Koji	PPT01.03	Kim, Hong Kwan	OA02.05	Li, Jina	PV01.07
Inaba, Megumi	PPT02.01	Kim, Hye Sook	PP01.29	Li, Kelly	PP01.18
Inagaki, Takashi	PP01.09	Kim, Hyeong Ryul	PP02.14	Li, Lezhi	PV01.07
Incharoen, Pimpin	PP02.29	Kim, Ju Won	PP01.29	Li, Lin	OA02.04
Indriani, Sri Indah	PP02.09	Kim, Jung Sun	PP01.29	Li, Lin	OA02.04
Infante-González, Cesar	PP01.17	Kim, Sang-We	PP01.02	Li, Ming	PV01.08
Inoue, Koji	PP01.06	Kim, Tae Min	OA02.06	Li, Tao	OA02.04
Inoue, Kouji	PPT02.04	Kim, Yeul Hong	PP01.29	Li, Tong	PV01.07
Inoue, Masaaki	PP01.06	Kim, Young Hak	PP02.49	Li, Xiangfu	PP02.38
Inoue, Takako	PP01.13	Kim, Young Saing	PP01.29	Li, Yan	OA02.04
Ishida, Hiroo	PPT02.01	Kim, Young Tae	OA01.03, PP02.03	Li, Yi	PP02.12
Ishijima, Mikako	PP02.54	Kim, Young-chul	PP01.15	Liao, Bin-Chi	PP01.16
Ishikawa, Nobuhisa	PPT02.04	Kim, Young-Hoon	PP01.02	Liao, Ri-Qiang	PPT02.02
Ishioka, Yoshiko	PP02.32	Kim, Yu Jung	PP01.29	Liao, Wei-Yu	PP01.16
Ito, Kentaro	OA01.05	Kim, Yun Seok	PP02.48	Lim, Ah Reum	PP01.29
Ito, Takamasa	PP02.46	Kimura, Hirokazu	PP01.28	Lim, Seungtaek	PP01.29
Ito, Yumika	PP02.06	Kimura, Toru	PP01.28, PP01.34, PP02.25	Lim, Taekyu	PP01.29
Itoga, Masamichi	PP02.32	Kinhikar, Rajesh	PP02.39	Lin, Chengwei	PP01.39
Itotani, Ryo	PPT02.03	Kinoshita, Fumihiko	PP01.11	Lin, Chia-Chi	PPT01.02
Iwamura, Yachiyo	PP02.26	Kishi, Noriko	PPT02.03	Lin, Jessica J.	OA02.06
Iwasa, Tsutomu	PPT01.08, PPT01.01	Kishikawa, Takayuki	PPT02.01	Lin, Jiun-Han	PP01.35
Iwasaku, Masahiro	PP02.49	Kishino, Daizo	PP01.06	Lin, Yen-Ting	PPT01.04
Iwata, Hiromitsu	PP02.13	Kiura, Katsuyuki	PP01.06, PPT02.04	Liu, Si-Yang	PPT02.02
Izumi, Motohiro	PP01.04	Clunklin, Pitchayaponne	PP02.43	Liu, Si-Yang Maggie	PPT02.02
		Knetki-Wróblewska, Magdalena	PV01.05, PV01.06	Liu, Stephen V.	OA02.06
		Kobayashi, Kenji	PP02.51	Liu, Wei	OA02.04
		Kobayashi, Masaaki	PP02.49	Liu, Wenliang	PP02.33
		Kobayashi, Takayuki	PP01.03	Liu, Xia	PP02.38
		Koche, Richard	OA02.03	Liu, Xianling	OA02.04
		Kodama, Ken	PP02.41	Liu, Yi-Nan	PP01.30
		Kodani, Masahiro	PPT02.04	López Sánchez, Dennis	PP01.17
		Koh, Eitetsu	PP02.15	Lu, Hong-Lian	PPT02.02
		Kohno, Mikihiko	PP01.11	Lu, Shun	OA02.04
		Kohno, Takashi	PPT01.03	Lumjiaktase, Putthapoom	PP02.29
		Kohyama, Tadashi	PPT02.01	Luna, Herdee Gloriane	PP01.32
		Kondo, Haruhiko	PP02.02		
		Kongkarnka, Sarawut	PP02.43	M	
		Kosanpipat, Bongkotmas	PP02.11	Ma, Minghai	PP02.38
		Kouro, Taku	PP02.31	Ma, Rui	OA02.04
		Kowalski, Dariusz M.	PV01.05, PV01.06	Ma, Zhenghua	PP02.38
		Kozuki, Toshiyuki	PP01.13, PPT02.04	Madan, Renu	PP02.52
		Krzakowski, Maciej	PV01.05	Maeda, Jun	PP02.41
		Kukita, Yoji	OA02.01	Maeda, Yoshinobu	PP01.06
		Kumar, Alok	PP02.34	Makiguchi, Tomonori	PP02.32
		Kumar, Divyesh	PP02.52	Malavet, Jose	PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
		Kumar, Narendra	PP02.52		
		Kumar, Vijay	PP02.35	Mandal, Tanmoy Kumar	PP02.34
		Kundu, Sayan	PP02.34	Maniwa, Tomohiro	PP02.25
		Kunimasa, Kei	PP01.26	Manoharan, Anusha	PP02.40
		Kuo, Yao-Wen	OA02.02	Manoj, Parvathy	OA02.03
		Kurita, Yusuke	PP02.51	Marave, Raiza	PP01.24
		Kurosaki, Takashi	PPT01.08, PPT01.01	Marek, Jenna	PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23
		Kusumoto, Masahiko	PPT01.03		

Martínez Pérez, Aida Karen	PP01.17	Nakwan, Narongwit	PP02.37	Pernemalm, Maria	PP02.45
Masnari, Linda	PP01.41	Naoki, Katsuhiko	PP02.31	Phinyo, Phichayut	PP02.11
Masuda, Noriyuki	PP02.49	Neesanun, Sunee	PP01.20	Pires Ferreira, Ingrid Mendonça	PP02.07
Matías-Cruz, Venecia	PP01.17	Nguyen, Danny	OA02.06	Pluzański, Adam	PV01.05
Matsubara, Taichi	PP01.12	Nguyen, Diep	PP02.20, PP02.21	Pondevida, Venus	PP01.32
Matsubara, Taisuke	PP02.04	Nguyen Van, Nhung	PP02.36	Porras, Ben Joshua	PP01.32
Matsubayashi, Jun	PP02.04	Ni, Jianjiao	OA01.04	Prabhash, Kumar	PP02.39
Matsudo, Kyoto	PP01.11	Ninomiya, Takashi	PPT02.04	Prieto, Eloise	PP01.32
Matsui, Kaoru	PP02.49	Nishide, Yumiko	PP02.49		
Matsui, Yusuke	PP02.42	Nishikawa, Kazuo	PP01.09		
Matsumoto, Hiroki	PP02.46	Nishimura, Kunihiro	PP01.12		
Matsumoto, Hirotake	OA01.05, PP02.28	Nishimura, Yoshiharu	PP02.44	Qiu, Juan	OA02.03
Matsumoto, Shingo	PP01.13	Nishino, Masaya	PP01.27	Quintanal-Villalonga, Alvaro	OA02.03
Matsumoto, Yoshiya	PP01.04	Nishio, Kazuto	OA01.05		
Matsuo, Yukinori	PPT02.03	Nishioka, Nanako	PP01.08, PP01.10		
Matsutani, Noriyuki	PPT02.01	Nishioka, Naoya	PP01.26		
Mei, Wei	PV01.07	Nishiyama, Akihiro	PP01.26		
Melosky, Barbara	PP01.18	Nóbrega Costa, Paulo Roberto	PP02.07	Raharjo, Eyllin	PP01.41
Meng, Fanchen	PV01.08	Nomura, Kento	PP02.13	Reckamp, Karen L.	OA02.06
Mhaskar, Rahul	PP02.20, PP02.21	Noronha, Vanita	PP02.39	Rekhtman, Natasha	OA02.03
Mhatre, Ritesh	PP02.39	Norrasan, Natthawat	PP02.11	Ren, Siying	PP02.33
Mihara, Naoki	PPT01.03			Reungwetwattana, Thanyanan	PP02.29
Millward, Michael	OA02.06			Rudin, Charles	OA02.03
Mira, Ferdinand	PP01.32	O		Ruklerd, Thidarat	PP02.37
Misumi, Toshihiro	PPT02.01	Ochi, Nobuaki	PP01.06, PPT02.04	Ryu, Yeongha	PP02.08
Mitani, Seiichiro	PPT01.01	Ochi, Takahiro	PP02.15		
Mitsudomi, Tetsuya	PP01.26, PP01.27, PP02.16	Oda, Naohiro	PP01.06	S	
Mitsune, Ayumi	PP01.37	Ogawa, Koichi	PP01.04	Sa, Jason K.	PP01.29
Mitsuoka, Shigeki	PP01.04	Ogino, Hiroyuki	PP02.13	Sada, Ryota	PP01.28
Miura, Naoko	PP01.01	Oguma, Tsuyoshi	PPT02.03	Saeteng, Somcharoen	PP02.11, PP02.43
Miyake, Mototaka	PPT01.03	Oguri, Masanosuke	PP02.13	Saito, Go	PP02.28
Miyamoto, Satoshi	PP02.54	Oh, Hyung-Joo	PP01.15	Saito, Haruhiro	PP02.31
Miyawaki, Michiyo	PP01.09	Oh, In-Jae	PP01.15	Saito, Kazuya	PP02.49
Miyazaki, Teruo	PP02.04	Ohara, Shuta	PP01.27, PP02.16	Sakai, Hiroshi	PP01.13, PP01.14
Mizote, Yu	PP02.25	Ohashi, Takuya	PP02.44	Sakai, Kazuko	OA01.05
Mizowaki, Takashi	PPT02.03	Ohe, Yuichiro	PPT01.03, PP02.30	Sakairi, Yuichi	PP02.46
Mizuki, Fumitaka	PP01.01	Ohira, Tatsuo	PP02.04	Sakamaki, Yasushi	PP02.41
Mizuno, Takaaki	PPT01.03	Ohnishi, Hiroshi	PPT02.04	Sakamoto, Tomohiro	PP01.12, PP01.13
Mok, Jeongha	PPT01.07	Ohrui, Takashi	PP01.37	Sakane, Tadashi	PP02.13
Monnamo, Nanamon	PP02.29	Okada, Asuka	PP02.28	Sakata, Shinya	OA01.05
Monsen, Jo	PV01.10	Okami, Jiro	PP02.25	Sakata, Yoshihiko	PP02.28
Moodie, Carla	PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23	Okamoto, Tatsuro	PP01.11, PP01.12	Sakaue, Miki	PP02.25
		Oki, Masahide	PP01.12	Sampurno, Edi	PP01.23
		Okimura, Akira	PP02.06	Sánchez-Reyes, Roberto	PP01.17
Mori, Masahide	PP02.54	Okubo, Yu	PPT01.03	Sanvarinda, Pimtip	PP02.29
Morimoto, Kenji	PP02.49	Okuma, Yusuke	PP01.26, PP02.30	Sasada, Tetsuro	PP02.31
Morise, Masahiro	PP01.13, PP01.14	Okumura, Fumihiko	PP02.32	Sasage, Takayuki	PP02.42
Morishita, Momoko	PP02.30	Oliveira Barros, Ytallo	PP02.07	Sasaki, Takanobu	PP01.37
Morita, Ryo	PP01.07	Olczyn-Serementa, Marta	PV01.06	Sato, Kaito	PP02.42
Motoyama, Hideki	PP02.05	Omasa, Mitsugu	PP02.05	Sato, Yuki	OA01.05, PP01.12, PP02.28
Mukai, Masami	PPT01.03	Oranratnachai, Songporn	PP02.29	Sawa, Kenji	PP01.04
Mummudi, Naveen	PP02.39	Ose, Naoko	PP01.28, PP01.34, PP02.41	Sawabata, Noriyoshi	PP01.22
Munir, Sri Melati	PP02.09	Osoegawa, Atsushi	PP01.09	Seki, Nobuhiko	PPT02.01
Muro, Shigeo	PP01.22	Ota, Masahide	PP01.22	Seki, Yoshitaka	PP02.51
		Ota, Takayo	PP02.49	Sekine, Yasuo	PP02.15
		Otsu, Satoshi	PP01.09	Sembiring, Ruth E.	PP01.41
		Otsuki, Taiichiro	PP02.28	Sen, Triparna	OA02.03
		Otto, Gordon	PP01.13, PP01.14	Serizawa, Masakuni	PP01.26
		Ou, Sai-Hong Ignatius	OA02.06	Seto, Takashi	PP01.11
		Oya, Yuko	PP02.28	Sha, Nisargbhaj	OA02.03
		Ozasa, Hiroaki	PPT02.03	Shao, Yang	PV01.08
		Oze, Isao	PPT02.04	Sharma, Mansi	PV01.04
				Shibata, Kazuhiko	PPT02.01
		P		Shibayama, Takuo	PPT02.04
		Pai, Trupti	PP02.39	Shibuya, Yoshimi	PP01.07
		Paik, Paul	PP01.13, PP01.14	Shih, Jin-Yuan	PPT01.04, PP01.30, PP01.33, PP01.16
		Park, Cheol-Kyu	PP01.15		
		Park, Il Yeong	PP01.15	Shikada, Yasunori	PP01.01
		Park, In Kyu	OA01.03, PP02.03	Shim, Young Mog	OA02.05
		Park, Ji Eun	PP01.02	Shimada, Sumire	PPT01.01
		Park, Ji Hyeon	OA01.03, PP02.03	Shimoi, Masaki	PP01.27, PP02.16
		Park, Ji Hyun	PP01.02	Shimokawa, Mototsugu	PP01.01
		Park, Junhee	OA01.03, PP02.03	Shimokawa, Mototusgu	PP01.12
		Park, Samina	OA02.05	Shin, Dong Wook	OA02.05
		Park, Sehhoon	PPT02.06	Shin, Sang Won	PP01.29
		Patel, Amrith	PV01.04	Shinagawa, Naofumi	PP01.13
		Patil, Tejas	OA02.06	Shinno, Yuki	PP02.30
		Patil, Vijay	PP02.39	Shinohara, Wakako	PP02.51
		Paul, Vinai	PP01.20	Shintani, Yasushi	PP01.28, PP01.34, PP02.25, PP02.41
				Shiono, Satoshi	PP02.42


Shiotsu, Shinsuke	PP01.26, PP02.49	Tanaka, Kazuhisa	PP02.46	Wu, Lin	OA02.04
Shirai, Yukina	PP01.26	Tanaka, Ryota	PP02.02	Wu, Min	PV01.08
Shiraishi, Kenshiro	PPT02.01	Tanaka, Satoshi	PP02.28	Wu, Shang-Gin	PPT01.04, PP01.30, PP01.33
Shiraishi, Kouya	PPT01.03	Tani, Yoko	PP01.04	Wu, Yi-Long	PPT02.02
Shiraishi, Naoki	PPT01.08	Taniguchi, Hirokazu	OA02.03		
Shiratori, Toshihiro	PP02.32	Taniguchi, Yoshihiko	PP02.28	X	
Shukuya, Takehito	PP01.26	Tanimura, Keiko	PP01.26	Xia, Yu	OA02.04
Singh, Harkant	PP02.52	Tanizaki, Junko	PPT01.08	Xu, Lin	PV01.08
Singh, Harkirat	PV01.04	Tanizawa, Kiminobu	PPT02.03	Xu, Xiao	OA02.04
Singh, Navneet	PP02.52	Tantraworasin, Apichat	PP02.11, PP02.43		
Singla, Aditya Kumar	PP02.52	Tanuwiwardja, Reza Kurniawan	PP01.23	Y	
Siwachat, Sophon	PP02.11, PP02.43	Tanzawa, Shigeru	PPT02.01	Yagi, Yuki	PP02.26
Smith, Robert	OA01.01	Taptawee, Pattarawadee	PP02.37	Yamada, Hidehisa	PP02.26
Soeroso, Noni Novisari	PP01.21	Tasaka, Sadatomo	PP02.32	Yamada, Tadaaki	PP01.26, PP02.49
Soh, Junichi	PP01.27, PP02.16	Tateishi, Akiko	PPT01.03	Yamada, Takahiro	PP02.49
Song, Xia	OA02.04	Tavares de Carvalho, Eliane Nadine	PP02.07	Yamaguchi, Masafumi	PP01.11
Song, Yunjie	PP02.12	Teoh, View-Hune	PP02.29	Yamaguchi, Toshihiko	PP02.54
Spigel, David R.	OA02.06	Terao, Kimio	PPT01.01	Yamamoto, Hideki	PP01.28
Sreeramareddy, Chandrashekhar	PP02.40	Teraoka, Shunsuke	PP02.28	Yamamoto, Noboru	PP02.30
Su, Kang-Yi	PP01.30	Terashima, Masaaki	PP02.49	Yamamoto, Nobuyuki	OA01.05, PP01.12
Su, Li	PP02.12	Tew, Jenna	PP02.18, PP02.19, PP02.20, PP02.21, PP02.22, PP02.23	Yamamoto, Shoichiro	PPT02.04
Su, Yue-Chiu	PP01.38		PPT02.02	Yang, Chen	PV01.04
Suda, Kazuharu	PP02.02	Tian, Hong-Xia	PP02.39	Yang, Chih-hsin	PP01.31, PP01.33, PPT01.02, PP01.14
Suda, Kenichi	PP01.26, PP01.27, PP02.16	Tibdewal, Anil	PP01.12	Yang, Ching-Yao	PP01.16
Sugawara, Takafumi	PP01.37	Tobino, Kazunori	PP02.26	Yang, James Chih-Hsin	PP01.16
Sugimoto, Akira	PP01.04	Toji, Yuta	PP01.12, PP01.13	Yang, Jin-Ji	PP01.14
Sugimoto, Keisuke	PPT02.04	Tokito, Takaaki	PP02.49	Yang, Lulu	PP02.33
Sugimoto, Takeya	PP02.54	Tokuda, Shinsaku	PP02.22	Yang, Pan-Chyr	OA01.01
Sugio, Kenji	PP01.09	Tolozo, Eric	PP01.08, PP01.10	Yang, Xue-Ning	PPT02.02
Sukaraphat, Napawan	PP01.20	Tomi, Takahiro	PP02.29	Yano, Seiji	PP01.26
Sukaichai, Sitthi	PP01.20	Trachu, Narumol	OA02.06	Yano, Yukihiko	OA01.05, PP02.54
Suksombooncharoen, Thatthan	PP02.43	Tsai, Frank Yung-Chin	PP01.30	Yasugi, Masayuki	PPT02.04
Sun, Changbo	PP02.02	Tsai, Meng-Feng	PP01.30, PP01.16	Yata, Yumi	PP02.44
Sun, Jong-Mu	PPT02.06	Tsai, Tzu-Hsiu	PP01.39	Yatabe, Yasushi	PPT01.03
Sun, Sophie	PP01.18	Tsai, Ying-Huei	PP02.28	Yazaki, Yuki	PP02.04
Sung, Jae Sook	PP01.20	Tsukita, Yoko	PP01.27, PP02.16	Yi, Chengsheng	PP02.38
Supavavej, Archara	PP02.28	Tsutani, Yasuhiro	PV01.05, PV01.06	Yin, Rong	PV01.08
Suzuki, Hidekazu	PP02.46	Tysarowski, Andrzej		Yin, Wenda	PV01.08
Suzuki, Hidemi	PP02.42			Yip, Stephen	PP01.18
Suzuki, Jun	PPT01.01	U		Yokouchi, Hideki	PP02.41
Suzuki, Shinichiro	PPT01.08	Uchida, Jyunji	PP02.54	Yokoyama, Tatsuya	PP01.07
Syahruddin, Elisna	PP01.41, PP01.21, PP01.23	Uddin, Fathema	OA02.03	Yokoyama, Toshihide	OA01.05, PP01.06, PP01.12, PPT02.04
Szolowska, Malgorzata	PV01.06	Ueda, Yutaka	PPT02.04	Yonesaka, Kimio	OA01.05, PPT01.08, PPT01.01
		Uehara, Hisanori	PP01.26	Yoneyama, Masahiro	PPT02.03
		Uehara, Yuji	PP01.03	Yoon, Dayoung	PP01.29
		Ueno, Shuichi	PP02.49	Yoon, Hyung-eun	PP02.41
		Unaedi, Uun	PP01.23	Yoon, Shinkyo	PP01.02
				Yoon, Soon Ho	PP02.03
T				Yoshida, Kazushi	PP02.51
Tabata, Toshiharu	PP01.37			Yoshida, Takeshi	PPT01.01
Tabe, Chiori	PP02.32	V		Yoshida, Tatsuya	PP02.30
Tachibana, Keisei	PP02.02	Vioix, Helene	PP01.14	Yoshida, Yukihiko	PPT01.03
Tachihara, Motoko	OA01.05			Yoshida, Yusaku	PP02.49
Tada, Naoko	PP02.49	W		Yoshimoto, Naoki	PP01.04
Tahara, Hideaki	PP02.25	Wakiya, Midori	PP02.06	Yoshimura, Akihiro	PP01.26, PP02.49
Tai, Pei-Chen	PP01.31, PPT01.02	Wang, Hsin-Yi	PPT01.04	Yoshimura, Naruo	PP01.37
Taima, Kageaki	PP02.32	Wang, Jie	PV01.08	Yoshino, Ichiro	PP02.46
Tajarernmuang, Pattraporn	PP02.43	Wang, Qiming	OA02.04	Yoshizumi, Tomoharu	PP01.11
Takada, Ikki	PP02.04	Wang, Siwei	PV01.08	Yu, Baoping	PP02.38
Takada, Kazuki	PP01.01	Wang, Song-Rong	PPT02.02	Yu, Chong-Jen	PP01.16
Takahama, Takayuki	PPT01.08, PP01.12	Wang, Ying	PP01.18	Yu, Helena	OA02.03
Takahashi, Masato	PP01.07	Wang, Yuanyong	PV01.01	Yu, Yan	OA02.04, PP02.38
Takahashi, Toshiaki	PP01.26	Wang, Yu-Ting	PP02.17	Yun, Jae Kwang	PP02.14
Takamori, Shinkichi	PP01.01, PP01.11	Wang, Zhongmin	OA02.04		
Takano, Hironobu	PP02.26	Wannasopha, Yutthaphan	PP02.43	Z	
Takayama, Koichi	PP01.26, PP02.49	Waqar, Saiana	OA02.06	Zarate, Lorenzo	PP01.32
Takeda, Kazuya	PP01.37	Watanabe, Hikaru	PP02.42	Zhan, Yingqian	OA02.03
Takeda, Maiko	PP01.22	Watanabe, Kageaki	PP01.03	Zhang, Bixiang	PP02.38
Takeda, Masayuki	PPT01.08, PP01.22	Watanabe, Kazuhiko	PPT02.04	Zhang, Jia-Tao	PPT02.02
Takeda, Takayuki	PP01.26, PP02.49	Watanabe, Kenji	PP01.11	Zhang, Jingyuan	PV01.08
Takemoto, Shinnosuke	PP01.26	Watanabe, Masato	PP01.07	Zhang, Ruyang	PP02.12
Takemoto, Toshiki	PP01.27, PP02.16	Watanabe, Satoshi	PPT01.01	Zhao, Jun	PP01.14
Takemura, Yoshizumi	PP02.49	Watanabe, Shun-ichi	PP01.26	Zhao, Wei	OA02.04
Takenaka, Tomoyoshi	PP01.11	Watanabe, Tetsuya	PPT01.03	Zhong, Wen-Zhao	PPT02.02
Takeoka, Hiroaki	PP01.13	Watthanawongsa, Parada	PP01.04	Zhu, Dengbing	PP02.38
Takeuchi, Yoshiyuki	PP02.41	West III, William	PP02.11	Zhu, Hongyu	PV01.08
Takumi, Yohei	PP01.09		PP02.22, PP02.23	Zhu, Song	PV01.07
Tamiya, Nobuyo	PP02.49	Wo, Yang	PV01.01	Zhu, Zhengfei	OA01.04
Tamura, Tomoki	PP01.06	Wongwut, Thanida	PP02.11	Zimmermann, Ana Carolina	PP02.07
Tanaka, Hiroshi	PP01.13				
Tanaka, Hisashi	PP02.32, PPT02.01				
Tanaka, Kaoru	PPT01.08, PPT01.01				

Journal of Thoracic Oncology

Official Journal of the International Association for the Study of Lung Cancer

Editor-in-Chief: **Alex A. Adjei**, MD, PhD, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA

The **Journal of Thoracic Oncology (JTO)**, the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials, and translational or basic research), reviews, and opinion pieces. The audience consists of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists with a special interest in thoracic oncology.



2021 Journal
Impact Factor*

20.121

*Journal Citation Reports®
(Clarivate Analytics, 2022)

ISSN: 1556-0864

A subscription to **JTO** is a benefit of membership in the IASLC. To join, visit www.IASLC.org.

08

Industry Supporters & Exhibitors



#ACLC22



Industry Supporters and Exhibitors

The IASLC 2022 Asia Conference on Lung Cancer would like to thank the following companies for their support:

GOLD LEVEL SUPPORT:



ELEVATION
ONCOLOGY

EXHIBITORS:



INDUSTRY SYMPOSIA SPONSORS:



09

General Information



#ACLC22



General Information

HEALTH & SAFETY MEASURES

ACLC 2022 will be hosted as an in-person meeting in Nara, Japan at the Nara Prefectural Convention Center. The health and safety of all our stakeholders are of the utmost importance. Although we are excited to welcome you to Nara, all necessary precautions will be taken to ensure a safe environment throughout the Conference.

The following measures will be put in place and enforced on-site to achieve this commitment (applicable to all staff, delegates, exhibitors, sponsors, and guests):

MASKS AND FACE COVERINGS

In accordance with the Japanese Ministry of Health, Labor and Welfare, the wearing of masks is mandatory at the Nara Convention Center and will be enforced.

By registering to attend, you agree that:

- You will not attend if you have any COVID-19 symptoms
- If during your attendance you develop any COVID-19 symptoms, you will immediately:
 - Self-isolate;
 - Comply with all local/national government restrictions; and
 - Inform the ACLC 2022 Conference Secretariat by email (aclc022-registration@icsevents.com).

IASLC and their suppliers will in their best effort, provide a safe environment to meet. It is expected that all participants will follow the measures to help reduce the risk.


Please note: There will be no on-site testing facility available at ACLC 2022.

ACCESS/SECURITY

Attendees are requested to wear their name badges at all times in order to participate in the Scientific Sessions and Exhibition. A 50 USD fee applies for any name badge reprints due to lost name badges.

OPENING HOURS

Registration Desk


 Lobby, 2F

Thursday, October 27	09:30 - 18:00
Friday, October 28	08:00 - 16:00
Saturday, October 29	07:00 - 13:15

Networking Lunch & Breaks


Thursday, October 27	Lunch Break: 12:00 - 12:30 Plenary Hall Room 203 2F PM Break: 15:00 - 15:45 Exhibit Hall Room 201+202 2F
Friday, October 28	AM Break: 10:15 - 10:45 Exhibit Hall Room 201+202 2F PM Break: 15:30 - 16:00 Exhibit Hall Room 201+202 2F
Saturday, October 29	AM Break: 10:15 - 10:45 Exhibit Hall Room 201+202 2F

Exhibit Hours

 Exhibit Hall, Room 201+202, 2F

Thursday, October 27	12:00 - 19:00
Friday, October 28	10:00 - 18:30
Saturday, October 29	10:00 - 13:50

Prayer / Mothers Room

 Room 105, 1F

Thursday, October 27	09:30 - 20:00
Friday, October 28	08:00 - 19:30
Saturday, October 29	07:00 - 14:30


Speaker Preview Center

 Waiting Room N, 2F

Thursday, October 27	09:30 - 17:00
Friday, October 28	08:00 - 16:00
Saturday, October 29	07:00 - 13:15



Poster Viewing

 Exhibit Hall, Room 201+202, 2F

Poster Session 1 Thursday, October 27

Poster Display Time	Entire Conference
Poster Tour 1 & 2	18:00 - 19:00
Poster Viewing Reception A	18:00 - 19:00

Topics for Poster Session 1

- Advanced/Metastatic NSCLC - Immunotherapy
- Advanced/Metastatic NSCLC - Targeted Therapy
- Translational Science, Pathology and Basic Science

Poster Session 2 Friday, October 28

Poster Display Time	Entire Conference
Poster Tour 3	17:00 - 18:30
Poster Viewing Reception B	17:00 - 18:30

Topics for Poster Session 2

- Diagnosis, Imaging and Bronchoscopy
- Early Stage NSCLC
- Locally Advanced NSCLC
- Palliative and Supportive Care

General Information



ACCESS VIRTUAL RECORDINGS (VIRTUAL PLATFORM)

All Scientific sessions will be audio recorded and made available on the Virtual Platform within 24 hours. The Virtual Platform also includes presentations slides, abstracts, and electronic versions of most posters. Log-in details including passwords were sent to your registered email in the Final Registration Confirmation email.

If you need assistance, please contact:
ACLC2022-Registration@icsevents.com.

Access to the ACLC 2022 Virtual Platform at:
<https://aclc22-iaslc.junolive.co/>



CERTIFICATE OF ATTENDANCE

Delegates can download their 'Certificate of Attendance' after completing the online Conference evaluation form sent to you by email at the conclusion of the Conference.

The IASLC ACLC 2022 is not accredited and does not provide CME credits or certifications for attending sessions.



WIFI

Wi-Fi will be provided in the meeting space area.

Network Name: **meeting-room200**

Password: **naracc01**



LOST & FOUND

Lost and found items should be returned / claimed at the **Registration Desk**.



Immunohistochemistry is an extremely valuable and powerful technique for pathologic diagnosis.

Published by the IASLC and its Pathology Committee, the IHC Atlas takes a comprehensive look at diagnostic IHC and its role in thoracic pathology.

The IHC Atlas is a useful reference for anyone interested in thoracic tumor diagnostics, from basic researchers to practicing oncologists. All pathologists should have access to these best practices. The Atlas is available in multiple languages.

Scan the QR code to order your copy today!



IASLC



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

IASLC ATLAS OF DIAGNOSTIC IMMUNOHISTOCHEMISTRY

EDITED BY

Yasushi Yatabe, MD, PhD
Alain C. Borczuk, MD
Wendy A. Cooper, MBBS, Bsc(Med), FRCPA, PhD
Sanja Dacic, MD, PhD
Keith M. Kerr, MD, FRCPATH, FRCPE
Andre L. Moreira, MD, PhD
Ming Sound Tsao, MD, FRCPC

IASLC



Conquering Thoracic Cancers Worldwide

Coming Soon!

**IASLC Atlas on
Molecular Biomarker
Testing for Targeted
Therapy**

Available in February 2023

JTO

CLINICAL AND RESEARCH REPORTS

JTO Clinical and Research Reports is the official open access journal of the International Association for the Study of Lung Cancer. It aims to complement the *Journal of Thoracic Oncology* by offering authors a gold open access publication option and publishing of the following article types in particular:

- Phase I trials
- Well-performed single-arm phase II trials
- Small to moderate-sized randomized phase II trials
- Subset analyses of published trials
- Impactful retrospective studies
- Database and registry analysis
- Large institutional series
- High-quality case reports
- Region-specific clinical trials
- Subspecialty specific thoracic oncology studies
- Selected high-quality meeting reports



**Now indexed in
PubMed Central!**

IASLC | INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



jtocr.org

IASLC 2023

MEETINGS SCHEDULE

IASLC 2023 Latin America Conference on Lung Cancer

January 25-27, 2023
Montevideo, Uruguay
#LALCA23

IASLC 2023 Targeted Therapies of Lung Cancer Meeting

February 22-25, 2023
Santa Monica, California, USA
#TTLC23

IASLC 2023 World Conference on Lung Cancer

September 9-12, 2023
Singapore
#WCLC23



INTERNATIONAL
ASSOCIATION
FOR THE STUDY
OF LUNG CANCER
Conquering Thoracic Cancers Worldwid

[IASLC.org/Meetings-Webinars](https://iaslc.org/Meetings-Webinars)

Scan the
QR code for
information
on upcoming
meetings and
webinars.



CONNECT WITH US

@IASLC


facebook.com/IASLC

@iaslungcancer

linkedin.com/IASLC

IASLC

* Location and dates subject to change



Join the IASLC Today!

Scan the QR code & enter
ACLCNewMember2022
to receive half off membership dues for one year.



INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER
Conquering Thoracic Cancers Worldwide



Podcasts



Research & Education



Staging



IASLC Meeting Discounts

Patient Advocacy



Fellowships



Publications



ILCN



Scientific Expertise



Membership

